REDWOOD CITY, Calif., Jan. 22, 2020 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of the Company's HF10™ therapy for patients with chronic pain.  Results will be presented at the North American Neuromodulation Society (NANS) meeting held in Las Vegas, January 24-26, 2020.

Dr. Erika Petersen, Director of Functional and Restorative Neurosurgery at UAMS, and lead Principal Investigator for the SENZA-PDN study, will present primary endpoint data and other study results on Saturday, January 25, 2020 from 7:00-7:10 a.m. PDT.  The SENZA-PDN study, which compares HF10 therapy plus Conventional Medical Management (CMM) to CMM alone in patients with painful diabetic neuropathy.  A total of 216 patients at 18 centers in the United States were enrolled in the study and enrollment was completed in August 2019.

"I would like to thank the many investigators furthering the field of neuromodulation and expanding the growing body of clinical evidence supporting HF10 therapy," said D. Keith Grossman, Chairman, CEO and President of Nevro.  "We are excited for Dr. Petersen to share the significant data from the SENZA-PDN trial at NANS, reflecting our commitment to helping physicians treat a large and underserved patient population suffering from chronic pain.  Additionally, we are pleased the many other clinical investigators studying HF10 will have the opportunity to present the results of their studies."

About Nevro
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in ≥65% of patients across six peer-reviewed clinical studies. The Senza^® System, Senza II™ System, and the Senza^® Omnia™ System are the only SCS systems that deliver Nevro's proprietary HF10^® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.

To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.

Investor Relations:
Juliet Cunningham
Vice President, Investor Relations
+1 650-433-3247
[email protected]